Purple Biotech Ltd. · TASE:PPBT

Purple Biotech — Kitov Pharmaceuticals Holdings — Investor Presentation (January 2017)

13 slides from Purple Biotech's investor presentation, Jan 23, 2017

  1. Slide 1: TyrNovo's NT 219: A New Concept in Cancer Therapy

     Thank you Streamlined Innovative Drug Development TyrNovo’s NT 219 A New Concept in Cancer Therapy January 23 , 2017 © 2017 Proprietary and Confidential

  2. Slide 2: Forward Looking Statements and Kitov's Safe Harbor Statement

     Forward Looking Statements and Kitov’s Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looking statements within the meaning of the safe harbor provisions of the

  3. Slide 3: Agenda

     ϯ Agenda • TyrNovo’s NT 219 : A New Concept in Cancer Therapy o Technology Highlights o Mechanism of Action o Patient Derived Xenograft Results o Business Opportunity • TyrNovo Transaction Highlights • KIT - 302 Recent Achievements and Milestones • Kitov’s Strategy

  4. Slide 4: NT 219 Technology Highlights

     ϰ NT 219 - Technology Highlights • NT 219 is a small molecule developed jointly by Alexander Levitzki , Ph.D., (Laureate of the 2005 Wolf Prize in Medicine) a professor at the Hebrew University of Jerusalem and Hadas Reuveni, Ph.D., co - founder and CTO of TyrNovo • NT 219 overcomes drug resistanc

  5. Slide 5: NT 219 Mechanism of Action

     NT 219 - Mechanism of Action ϱ • Anti - cancer drugs induce feedback activation of two major pathways, the STAT 3 and the IRS, leading to drug resistance • NT 219 effectively targets these feedback pathways and thereby overcomes drug resistance and extends the positive response to the drugs • Inhi

  6. Slide 6: NT 219 Prevents Acquired Resistance to Erlotinib in Head & Neck Tumors

     ϲ Response Erlotinib: Acquired resistance NT 219 prevents resistance to Erlotinib NT 219 : 100 Tumor Regression of Patient - Derived Head & Neck Cancer Implanted in mice (PDX model) Days (n= 8 ) (n= 8 ) (n= 8 ) (n= 8 ) NT 219 Demonstrated to Prevent Acquired Resistance of Head & Neck Tumors to EGF

  7. Slide 7: NT 219 Converted Non-Responding Pancreatic Tumors to Responders

     NT 219 Successfully Converted Non - Responding Pancreatic Tumors to Responders to Gemcitabine (Gemzar ® ) Non - Responders Responders Tumor Regression of Patient - Derived Pancreatic Cancer Implanted in mice (PDX model) ϳ

  8. Slide 8: NT 219 Synergistic Immunotherapeutic Effect with Cetuximab

     ϴ NT 219 Shown to Have Synergistic I mmunotherapeutic E ffect with Anti - EGFR Ab Cetuximab (Erbitux ®) Initial results demonstrated that NT 219 has promising immunotherapeutic potential PBMCs (patient derived) Three treatments (days 0 , 3 , 10 ) Cetuximab - treated mice Cetuximab+NT 219 - treated

  9. Slide 9: NT 219 Business Opportunity

     NT 219 Business Opportunity ϵ * Global Data • NT 219 has the potential to be combined with numerous oncology drugs, and to expand the efficacy duration, target patient population, and patent lifespan of the applicable drugs • Accumulated annual sales of the relevant cancer drugs exceeds $ 6 B • Im

  10. Slide 10: Transaction Highlights

     Transaction Highlights ϭϬ • Kitov purchased all shares held by majority shareholder ( 56 %) • Total consideration of $ 3.8 M: o $ 2 M in cash o $ 1.8 M in Kitov shares ( 6.8 % of Kitov issued & outstanding; shares subject to lock - up & standstill) • Possible additional purchase of minority share

  11. Slide 11: KIT-302 Recent Achievements and Milestones

     KIT - 302 Recent Achievements and Milestones ϭϭ Q 2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2016 2017 2018 JUNE Completed initial stability study AUGUST U.S . Patent issued Q 1 ’ 17 Anticipated NDA Submission to FDA Q 1 ’ 18 Expected FDA Clearance for Marketing MAY ▪ Received FDA minutes that support NDA submission

  12. Slide 12: Kitov's Strategy

     Kitov’s Strategy ϭϮ x Establish a diverse pipeline that will drive long term value creation for our shareholders x Harness our team’s proven track record in drug development x Leverage the benefits of out - licensing our late - stage / approved drugs (e.g. KIT - 302 ) in order to support pipeline

  13. Slide 13: Thank you

      Thank you Streamlined Innovative Drug Development Company Headquarters One Azrieli Center Round Tower 132 Menahem Begin Road Tel Aviv 6701101 , Israel US Medical Research Office 1615 Suter's Lane NW Washington DC 20007 Contact Us Tel : + 972 - 3 - 9333121 Email: Info@kitovpharma.com www.kitovpha

Kitov Pharmaceuticals Holdings — Investor Presentation (January 2017) on 6ix